CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , April 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the ...

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...

Harbour BioMed has built a strong foundation in antibody discovery and development, underpinned by its advanced technology ...

(RTTNews) - HBM Holdings Limited or Harbour BioMed (HBMHF) Wednesday said that Youchen Chen has been appointed as the new Chief Financial Officer. Chen will be based in Shanghai and Hong Kong SAR ...

Under the collaboration agreement, the parties will combine Harbour BioMed's industry-leading technology platform, proprietary dataset and extensive expertise in antibody development with Insilico ...

It is entering into two partnerships and licencing agreements with Harbour BioMed for multi-specific antibody discovery, and a third with Syneron Bio for macro-cyclic peptides development.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , April 9, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ...